Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Meldgaard

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of Neuroinflammation|July 21, 2014
No effect of ablation of surfactant protein-D on acute cerebral infarction in miceKate L Lambertsen, Kamilla Østergaard, Bettina H Clausen, et al.
Nucleic Acid Therapeutics|August 20, 2013
Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification patternPeter H Hagedorn, Victor Yakimov, Søren Ottosen, et al.
BMJ Open|October 25, 2011
A possible association between a dysfunctional skin barrier (filaggrin null-mutation status) and diabetes: a cross-sectional studyJacob P Thyssen, Allan Linneberg, Berit C Carlsen, et al.
Environmental Health Perspectives|January 2, 2014
Associations of filaggrin gene loss-of-function variants with urinary phthalate metabolites and testicular function in young Danish MenUlla Nordström Joensen, Niels Jørgensen, Michael Meldgaard, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 6, 2009
Microglia protect neurons against ischemia by synthesis of tumor necrosis factorKate Lykke Lambertsen, Bettina Hjelm Clausen, Alicia Anne Babcock, et al.
The Journal of Allergy and Clinical Immunology|November 18, 2011
Interaction between filaggrin null mutations and tobacco smoking in relation to asthmaNikolaj Drimer Berg, Lise Lotte N Husemoen, Betina Heinsbæk Thuesen, et al.
Molecular Therapy. Nucleic Acids|September 12, 2022
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathiesAmy Easton, Marianne L Jensen, Congwei Wang, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Neuroinflammation|July 21, 2014
No effect of ablation of surfactant protein-D on acute cerebral infarction in miceKate L Lambertsen, Kamilla Østergaard, Bettina H Clausen, et al.
Nucleic Acid Therapeutics|August 20, 2013
Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification patternPeter H Hagedorn, Victor Yakimov, Søren Ottosen, et al.
BMJ Open|October 25, 2011
A possible association between a dysfunctional skin barrier (filaggrin null-mutation status) and diabetes: a cross-sectional studyJacob P Thyssen, Allan Linneberg, Berit C Carlsen, et al.
Environmental Health Perspectives|January 2, 2014
Associations of filaggrin gene loss-of-function variants with urinary phthalate metabolites and testicular function in young Danish MenUlla Nordström Joensen, Niels Jørgensen, Michael Meldgaard, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 6, 2009
Microglia protect neurons against ischemia by synthesis of tumor necrosis factorKate Lykke Lambertsen, Bettina Hjelm Clausen, Alicia Anne Babcock, et al.
The Journal of Allergy and Clinical Immunology|November 18, 2011
Interaction between filaggrin null mutations and tobacco smoking in relation to asthmaNikolaj Drimer Berg, Lise Lotte N Husemoen, Betina Heinsbæk Thuesen, et al.
Molecular Therapy. Nucleic Acids|September 12, 2022
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathiesAmy Easton, Marianne L Jensen, Congwei Wang, et al.
Pageof 3